CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has proved helpful conscientiously but unsuccessfully to develop an one-time therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this treatment, CytoDyn has cast its net far and wide both geographically and in terms of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be used is actually an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as a combination treatment in the healing of multi-drug-resistant HIV have been closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of my past several shares. My first CytoDyn post, “CytoDyn: What to be able to Do When It is Too Good In order to Be True?”, set out all of the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such an extremely promotional image in the Uptick Newswire interview which I came away with a bad viewpoint of the business.

Irony of irony, the poor opinion of mine of the business has grown steadily, however, the disappointment hasn’t been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger yet still disappoints? Therein lies the story; permit me to explain.

CytoDyn acquired its much storied therapy (which I shall mean as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the therapy as well as reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti viral activity in HIV infected subjects. Today’s transaction of $3.5 zillion transfers ownership of this technology and also associated intellectual property coming from Progenics to CytoDyn, and roughly 25 million mg of majority drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 huge number of) along with the very first new drug program approval ($5 million), as well as royalty payments of 5 percent of net sales upon commercialization.

Since that time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to get a market place cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous therapies and numerous indications, it’s this single remedy as well as a “broad pipeline of indications” as it places it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a likely beneficial therapy in dozens of indications.

The opening banner of its on the website of its (below) shows an energetic organization with diverse interests albeit focused on leronlimab, several disease sorts, multiple delivering presentations and multiple publications.

Can it all be smoke and mirrors? That is a question I have been asking myself from the really start of the interest of mine in this particular organization. Judging with the multiples of a huge number of several comments on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am much from alone in this particular question.

CytoDyn is a traditional battleground, or some could say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News